Back to results
US 11,141,490 B2Granted
Antibody-drug conjugates based on gold compounds
AssigneesResearch Foundation of the City University of New York, Memorial Sloan Kettering Cancer Center
InventorsMaria Contel, Natalia Curado, Jason Lewis, Sophie Poty
Life of this patent
Estimating the term…
Abstract
Antibody-drug-conjugates (ADC) are provided having a structure of: wherein L is PR3 ligand. The ADC has n drug moieties bound to the Trastuzumab antibody such that the ADC has a drug-to-antibody ratio (DAR) between 2 and 4 and the drug moieties are bound to the Trastuzumab antibody through cysteine (S) or lystine (Lys) residues. The disclosed ADCs are particularly useful in treating breast cancer.
Claims6
A composition of matter comprising:
- wherein L is PR3 where R is alkyl or aryl or NHC heterocyclic carbene;
- the composition of matter has n drug moieties bound to the Trastuzumab antibody such that the composition of matter has a drug-to-antibody ratio (DAR) between 2 and 4 and the drug moieties are bound to the Trastuzumab antibody through cysteine residues.
Dependencies are inferred from the claim text.